Standards for Clinical Trials in Male and Female Sexual Dysfunction: I. Phase I to Phase IV Clinical Trial Design

被引:4
|
作者
Fisher, William A. [1 ,2 ]
Gruenwald, Ilan [3 ,4 ]
Jannini, Emmanuele A. [5 ]
Lev-Sagie, Ahinoam [6 ]
Lowenstein, Lior [7 ]
Pyke, Robert E. [8 ]
Reisman, Yakov [9 ]
Revicki, Dennis A. [10 ]
Rubio-Aurioles, Eusebio [11 ,12 ]
机构
[1] Western Univ, Dept Psychol, London, ON N6A 5C2, Canada
[2] Western Univ, Dept Obstet & Gynaecol, London, ON N6A 5C2, Canada
[3] Rambam Med Ctr, Dept Urol, Haifa, Israel
[4] Rambam Med Ctr, Neurourol Unit, Haifa, Israel
[5] Univ Rome, Dept Syst Med, Endocrinol & Med Sexol, Tor Vergata, Italy
[6] Hadassah Hebrew Univ, Med Ctr, Dept Obstet & Gynecol, Jerusalem, Israel
[7] Rambam Med Ctr, Dept Obstet & Gynecol, Haifa, Israel
[8] Pykonsult LLC, New Fairfield, CT USA
[9] Amstelland Hosp, Med Director Sexual Clin, Amstelveen, Netherlands
[10] Evidera, Outcomes Res, Bethesda, MD USA
[11] Asociac Mexicana Salud Sexual, AC, Mexico City, DF, Mexico
[12] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico
来源
JOURNAL OF SEXUAL MEDICINE | 2016年 / 13卷 / 12期
关键词
Clinical Trials; Male Sexual Dysfunction; Female Sexual Dysfunction; PREMENOPAUSAL WOMEN EFFICACY; ERECTILE DYSFUNCTION; DOUBLE-BLIND; DISORDER; FLIBANSERIN; SAFETY;
D O I
10.1016/j.jsxm.2016.09.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This series of articles outlines standards for clinical trials of treatments for male and female sexual dysfunctions, with a focus on research design and patient-reported outcome assessment. These articles consist of revision, updating, and integration of articles on standards for clinical trials in male and female sexual dysfunction from the 2010 International Consultation on Sexual Medicine developed by the authors as part of the 2015 International Consultation on Sexual Medicine. We are guided in this effort by several principles. In contrast to previous versions of these guidelines, we merge discussion of standards for clinical trials in male and female sexual dysfunction in an integrated approach that emphasizes the common foundational practices that underlie clinical trials in the two settings. We present a common expected standard for clinical trial design in male and female sexual dysfunction, a common rationale for the design of phase I to IV clinical trials, and common considerations for selection of study population and study duration in male and female sexual dysfunction. We present a focused discussion of fundamental principles in patient-(and partner-) reported outcome assessment and complete this series of articles with specific discussions of selected aspects of clinical trials that are unique to male and to female sexual dysfunction. Our consideration of standards for clinical trials in male and female sexual dysfunction attempts to embody sensitivity to existing and new regulatory guidance and to address implications of the evolution of the diagnosis of sexual dysfunction that have been brought forward in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. The first article in this series focuses on phase I to phase IV clinical trial design considerations. Subsequent articles in this series focus on the measurement of patient-reported outcomes, unique aspects of clinical trial design for men, and unique aspects of clinical trial design for women. Copyright (C) 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1805 / 1817
页数:13
相关论文
共 50 条
  • [11] The i3+3 design for phase I clinical trials.
    Ji, Yuan
    Liu, Meizi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [12] Approximate Bayesian computation design for phase I clinical trials
    Jin, Huaqing
    Du, Wenbin
    Yin, Guosheng
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (12) : 2310 - 2322
  • [13] What should be the ideal design of phase I clinical trials?
    Lau, Derick
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S76 - S76
  • [14] The role of translational research in the design of phase I clinical trials
    Belka, C
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S136 - S136
  • [15] DESIGN AND ANALYSIS OF PHASE-I CLINICAL-TRIALS
    STORER, BE
    BIOMETRICS, 1989, 45 (03) : 925 - 937
  • [16] ABBREVIATED PHASE-I CLINICAL-TRIAL OF IV MITOZOLOMIDE
    JOSS, RA
    RYSSEL, HJ
    BISCHOFF, AK
    GOLDHIRSCH, A
    BRUNNER, KW
    CANCER TREATMENT REPORTS, 1986, 70 (06): : 797 - 798
  • [17] PHASE-I CLINICAL-TRIAL OF IV CARMINOMYCIN (CMM)
    ABELE, R
    ROZENCWEIG, M
    REICH, SD
    LENAZ, L
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 329 - 329
  • [18] An application of a factorial design to a phase I clinical trial.
    Carr, A
    Montague, TH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P64 - P64
  • [19] Phase I and II clinical trial design for targeted agents
    Richard L. Schilsky
    Targeted Oncology, 2006, 1 : 220 - 227
  • [20] Phase I and II clinical trial design for targeted agents
    Schilsky, Richard L.
    TARGETED ONCOLOGY, 2006, 1 (04) : 220 - 227